(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 5.02% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.14%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.18%.
Gilead Sciences's revenue in 2026 is $29,736,000,000.On average, 34 Wall Street analysts forecast GILD's revenue for 2026 to be $38,266,425,086,554, with the lowest GILD revenue forecast at $36,185,553,977,730, and the highest GILD revenue forecast at $40,172,234,843,144. On average, 33 Wall Street analysts forecast GILD's revenue for 2027 to be $40,595,610,170,178, with the lowest GILD revenue forecast at $37,699,027,654,136, and the highest GILD revenue forecast at $44,121,668,612,338.
In 2028, GILD is forecast to generate $42,717,453,084,844 in revenue, with the lowest revenue forecast at $37,931,201,220,574 and the highest revenue forecast at $49,692,592,636,976.